Skip to main content

Advertisement

SpringerLink
Log in

Hepatotoxicity

Liver fibrosis with methotrexate — an overestimated risk?

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

A prospective study suggests that the risk of liver fibrosis with methotrexate treatment has been overestimated. The findings suggest the need to reconsider the intensive strategies and the screening tools that are recommended for monitoring liver fibrosis in patients receiving methotrexate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Proposed relationship between methotrexate treatment and liver fibrosis.

References

  1. Zachariae, H. Methotrexate side-effects. Br. J. Dermatol. 122 (Suppl. 36), 127–133 (1990).

    Article  PubMed  Google Scholar 

  2. Whiting-O’Keefe, Q. E., Fye, K. H. & Sack, K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90, 711–716 (1991).

    Article  PubMed  Google Scholar 

  3. Arena, U. et al. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig. Liver Dis. 44, 149–153 (2012).

    Article  CAS  PubMed  Google Scholar 

  4. Atallah, E. et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.12.034 (2023).

    Article  PubMed  Google Scholar 

  5. Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).

    Article  PubMed  Google Scholar 

  6. Selvaraj, E. A. et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 75, 770–785 (2021).

    Article  PubMed  Google Scholar 

  7. Warren, R. B. et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br. J. Dermatol. 175, 23–44 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación Biomédica de Málaga-IBIMA-Plataforma BIONAND, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain

    Raul J. Andrade

  2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

    Raul J. Andrade

  3. Faculty of Medicine, University of Iceland, Reykjavík, Iceland

    Einar S. Björnsson

  4. Department of Gastroenterology, Landspitali University Hospital Reykjavík, Reykjavík, Iceland

    Einar S. Björnsson

Authors
  1. Raul J. Andrade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Einar S. Björnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raul J. Andrade.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrade, R.J., Björnsson, E.S. Liver fibrosis with methotrexate — an overestimated risk?. Nat Rev Gastroenterol Hepatol 20, 347–348 (2023). https://doi.org/10.1038/s41575-023-00782-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00782-3

  • Springer Nature Limited

This article is cited by

Search

Navigation